Form 4: Kymera CMO Sells Shares After Option Exercise

Kymera Therapeutics' Chief Medical Officer, Jared Gollob, exercised stock options and subsequently sold a portion of his shares under a pre-arranged trading plan.

Summary

• Jared Gollob, Chief Medical Officer of Kymera Therapeutics, Inc. (KYMR), reported transactions on October 15, 2025.
• The transactions involved the exercise of stock options and the subsequent sale of common stock, all executed under a Rule 10b5-1 trading plan dated June 2, 2025.
• Mr. Gollob acquired a total of 51,209 shares of common stock through option exercises: 28,999 shares at an exercise price of $1.31 and 22,210 shares at an exercise price of $2.08.
• He disposed of a total of 59,576 shares of common stock through sales at weighted average prices ranging from $60.37 to $63.0868.
• Following these transactions, Mr. Gollob's direct beneficial ownership of common stock is 109,992 shares.
• The stock options exercised were fully vested and exercisable.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While there is net insider selling, it was conducted under a pre-arranged 10b5-1 plan, which typically mitigates negative market interpretations. The executive also realized significant personal gains, which is a positive for the individual but not directly for the company's operational performance.

Positives

• The Chief Medical Officer realized significant profits by exercising options at very low prices ($1.31 and $2.08) and selling shares at substantially higher market prices (ranging from $60.37 to $63.0868).
• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned and systematic approach to managing equity holdings rather than a reaction to immediate company news.

Negatives

• The net effect of the transactions was a reduction in the Chief Medical Officer's direct beneficial ownership of common stock by 8,367 shares (59,576 sold vs. 51,209 acquired).

Risks

• Insider selling, even when pre-planned, can sometimes be perceived negatively by the market, potentially leading to questions about management's long-term confidence, though the 10b5-1 plan mitigates this concern.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This filing reports routine insider transactions and does not provide specific insights into broader industry trends or competitive landscape. It reflects an individual executive's equity management strategy.

Corporate Governance

Stakeholder Impact

• Shareholders: May observe a reduction in insider holdings, which could be interpreted in various ways, though the 10b5-1 plan context is important.
• Employees: No direct impact mentioned.

Key Dates

Recommendation

The filing details routine insider transactions executed under a pre-arranged 10b5-1 trading plan. While there was net selling, this is a common practice for executives to diversify holdings and manage liquidity. It does not inherently signal a change in the company's fundamental prospects or warrant a strong buy or sell recommendation based solely on this report. Investors should consider broader company performance and market conditions.

Keywords

Kymera Therapeutics, KYMR, Insider Trading, Form 4, Stock Options, Rule 10b5-1 Plan, Jared Gollob, Chief Medical Officer, Equity Sales